Standard BioTools Inc

Standard BioTools Inc

Standard BioTools Inc (ticker: LAB) develops and sells instruments, reagents and software used in life‑science research and molecular diagnostics. The company’s platforms are deployed with academic researchers, pharmaceutical and biotechnology organisations and clinical laboratories. With a market capitalisation of about $504.2m, it is a smaller‑cap participant in the life‑sciences tools segment; that size can result in greater share‑price volatility and sensitivity to research and industry capital expenditure cycles. Key investment considerations include the proportion of recurring consumables revenue, the timing of instrument orders, competitive pressure from larger vendors and any regulatory matters tied to diagnostic use. Financial results can be uneven as customers delay or accelerate spending, and technology shifts can alter the competitive landscape. Investors should view this as a growth‑oriented, higher‑risk exposure within healthcare tools, review recent financials and cash flow, and seek independent advice tailored to their circumstances.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Standard BioTools' stock as it has room for growth.

Above Average

Financial Health

Standard BioTools Inc is generating solid revenue and cash flow, indicating a stable financial position.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring LAB

Activist Sparks Life Science Shakeup

Activist Sparks Life Science Shakeup

Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.

Published: August 11, 2025

Explore Basket
Pharma's American Reshoring Wave

Pharma's American Reshoring Wave

AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.

Published: July 23, 2025

Explore Basket
3D-Bioprinted Tissues

3D-Bioprinted Tissues

These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

πŸ“ˆ

Growth Drivers

Recurring consumables and adoption of analytical platforms can support revenue growth, though demand may fluctuate with research funding and capital budgets.

🌍

Customer Mix

Customers include academic, biopharma and clinical labs worldwide; partnerships and institutional purchasing matter, but priorities and funding can vary.

⚑

Tech & Competition

Product innovation can create advantage, yet larger competitors and rapid technological change mean outcomes and performance can vary.

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

A

Agilent Technologies Inc.

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

ALGN

Align Technology Inc.

Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.

Frequently asked questions